The estimated Net Worth of Harry Shuman is at least 493 千$ dollars as of 20 August 2024. Harry Shuman owns over 5,000 units of Merus N.V stock worth over 477,761$ and over the last 5 years Harry sold MRUS stock worth over 15,519$.
Sign up
Harry Shuman MRUS stock SEC Form 4 insiders trading
Harry has made over 11 trades of the Merus N.V stock since 2022, according to the Form 4 filled with the SEC. Most recently Harry exercised 5,000 units of MRUS stock worth 251,400$ on 20 August 2024.
The largest trade Harry's ever made was exercising 8,300 units of Merus N.V stock on 10 June 2024 worth over 417,324$. On average, Harry trades about 1,667 units every 45 days since 2020. As of 20 August 2024 Harry still owns at least 9,502 units of Merus N.V stock.
You can see the complete history of Harry Shuman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Harry Shuman's mailing address?
Harry's mailing address filed with the SEC is C/O MERUS N.V., UPPSALALAAN 17, UTRECHT, P7, 3584 CT.
Insiders trading at Merus N.V
Over the last 5 years, insiders at Merus N.V have traded over 76,701,272$ worth of Merus N.V stock and bought 4,110,523 units worth 71,063,751$ . The most active insiders traders include Partners L P/Ilbiotechnolog...、Partners L P/Ilbiotechnolog...、Corp Incyte. On average, Merus N.V executives and independent directors trade stock every 18 days with the average trade being worth of 4,323,728$. The most recent stock trade was executed by Harry Shuman on 20 August 2024, trading 5,000 units of MRUS stock currently worth 251,400$.
What does Merus N.V do?
merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. our most advanced development programs use the biclonics® format. biclonics® are capable of simultaneously attacking tumors in multiple ways. for example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.
What does Merus N.V's logo look like?
Complete history of Harry Shuman stock trades at Merus N.V
Merus N.V executives and stock owners
Merus N.V executives and other stock owners filed with the SEC include:
-
Hui Liu,
Chief Business Officer and Head of Merus U.S. -
Dr. Sven Ante Lundberg M.D.,
CEO, Pres, Principal Financial Officer & Exec. Director -
Peter B. Silverman J.D.,
Exec. VP, Gen. Counsel, Chief Intellectual Property Officer and Head of Utrecht & US Legal -
Hui Liu,
Chief Bus. Officer, Exec. VP & Head of Merus U.S. -
Alexander Bakker,
Chief Development Officer -
Peter Silverman,
General Counsel, Chief Intellectual Property Officer and Head of US Legal -
John de Kruif,
Chief Technology Officer -
Sven Lundberg,
President, Chief Executive Officer, Principal Financial Officer, Executive Director -
Anand Mehra,
Non-Executive Independent Chairman of the Board -
Andrew Joe,
Chief Medical Officer -
Paolo Pucci,
Non-Executive Independent Director -
Victor Sandor,
Non-Executive Independent Director -
Jillian Connell,
Investor Relations & Corporate Communications -
Leonard Kanavy,
Non-Executive Independent Director -
Gregory Perry,
Independent Non-Executive Vice Chairman of the Board -
Mark Iwicki,
Non-Executive Independent Director -
Shannon Campbell,
Exec. VP & Chief Commercial Officer -
Dr. Cecile A.W. Geuijen Ph.D.,
Chief Scientific Officer -
Anne Noordzij,
Sec. -
Dr. Ellen Broug,
Exec. Director of IP & Sec. -
Dr. Andrew Joe M.D.,
Chief Medical Officer -
Alexander Berthold Hendrik Bakker Ph.D.,
Chief Devel. Officer & Sr. VP -
Cornelis Adriaan de Kruif Ph.D.,
CTO & Sr. VP -
Dr. Hennie Hoogenboom,
Co-Founder and Scientific Advisor -
Partners L P/Ilbiotechnolog...,
-
Lex Bakker,
SVP, Chief Development Officer -
Mark Throsby,
EVP & Chief Scientific Officer -
Partners L P/Ilbiotechnolog...,
-
Corp Incyte,
10% owner -
Cecile A W Geuijen,
SVP & Chief Scientific Officer -
Jason Haddock,
-
Maxine Gowen,
-
Len Kanavy,
-
Harry Shuman,
VP Controller, PAO -
Fabian Zohren,
Chief Medical Officer